AI scans and blood tests could predict who responds to stomach cancer chemotherapy

NCT ID NCT07697079

Not yet recruiting Knowledge-focused Sponsor: Liu Yang Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study is testing whether artificial intelligence can predict how well stomach cancer patients will respond to chemotherapy given before surgery. Researchers will collect CT scans, ultrasound images, and blood samples from 300 patients with locally advanced gastric cancer. Using deep learning, they aim to build a model that identifies good versus poor responders, potentially allowing doctors to personalize treatment plans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a non-invasive way to predict which patients will benefit from chemotherapy, helping tailor treatment and avoid unnecessary side effects.
What could go wrong: This is an early-stage observational study, not a treatment trial. The AI model may not be accurate enough for clinical use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

QianfoshanH

Jinan, Shandong, 250014, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.